secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001628280-24-035603
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q2 net loss narrows to $45.8M; LYL797 shows 40% ORR in TNBC
------------------------------------------------------------------------------

- Net loss of $45.8M ($63.9M in Q2 2023); non-GAAP net loss $39.1M ($45.6M).
- Cash, equivalents and marketable securities $491.1M as of June 30, 2024, funding operations into 2027.
- LYL797 Phase 1: 40% objective response rate and 60% clinical benefit rate at 150x10^6 cells in relapsed/refractory TNBC.
- FDA cleared IND for LYL119 (next-gen ROR1 CAR T); Phase 1 to start in ROR1+ ovarian/endometrial cancers.
- R&D expenses decreased to $40.3M; G&A expenses to $12.3M, driven by November 2023 workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/0001628280-24-035603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024035603/lyel-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer